Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
Abstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-020-05148-7 |
id |
doaj-55b92bfe41824b28a7f9b6e4bccd7553 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Magnus Unemo Marit Hansen Ronza Hadad Mirja Puolakkainen Henrik Westh Kaisu Rantakokko-Jalava Carina Thilesen Michelle J. Cole Iryna Boiko Pham T. Lan Daniel Golparian Shin Ito Martin Sundqvist |
spellingShingle |
Magnus Unemo Marit Hansen Ronza Hadad Mirja Puolakkainen Henrik Westh Kaisu Rantakokko-Jalava Carina Thilesen Michelle J. Cole Iryna Boiko Pham T. Lan Daniel Golparian Shin Ito Martin Sundqvist Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants BMC Infectious Diseases Finnish new variant Chlamydia trachomatis Aptima combo 2 23S rRNA Validation Surveillance |
author_facet |
Magnus Unemo Marit Hansen Ronza Hadad Mirja Puolakkainen Henrik Westh Kaisu Rantakokko-Jalava Carina Thilesen Michelle J. Cole Iryna Boiko Pham T. Lan Daniel Golparian Shin Ito Martin Sundqvist |
author_sort |
Magnus Unemo |
title |
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants |
title_short |
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants |
title_full |
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants |
title_fullStr |
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants |
title_full_unstemmed |
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants |
title_sort |
sensitivity, specificity, inclusivity and exclusivity of the updated aptima combo 2 assay, which provides detection coverage of the new diagnostic-escape chlamydia trachomatis variants |
publisher |
BMC |
series |
BMC Infectious Diseases |
issn |
1471-2334 |
publishDate |
2020-06-01 |
description |
Abstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity of the updated AC2 for the detection of CT and Neisseria gonorrhoeae (NG) on the automated Panther system (Hologic). Methods We examined 1004 clinical AC2 samples and 225 analytical samples spiked with phenotypically and/or genetically diverse NG and CT strains, and other potentially cross-reacting microbial species. The clinical AC2 samples included CT wild type (WT)-positive (n = 488), all four described AC2 diagnostic-escape nvCTs (n = 170), NG-positive (n = 214), and CT/NG-negative (n = 202) specimens. Results All nvCT-positive samples (100%) and 486 (99.6%) of the CT WT-positive samples were positive in the updated AC2. All NG-positive, CT/NG-negative, Trichomonas vaginalis (TV)-positive, bacterial vaginosis-positive, and Candida-positive AC2 specimens gave correct results. The clinical sensitivity and specificity of the updated AC2 for CT detection was 99.7 and 100%, respectively, and for NG detection was 100% for both. Examining spiked samples, the analytical inclusivity and exclusivity were 100%, i.e., in clinically relevant concentrations of spiked microbe. Conclusions The updated AC2, including two CT targets and one NG target, showed a high sensitivity, specificity, inclusivity and exclusivity for the detection of CT WT, nvCTs, and NG. The updated AC2 on the fully automated Panther system offers a simple, rapid, high-throughput, sensitive, and specific diagnosis of CT and NG, which can easily be combined with detection of Mycoplasma genitalium and TV. |
topic |
Finnish new variant Chlamydia trachomatis Aptima combo 2 23S rRNA Validation Surveillance |
url |
http://link.springer.com/article/10.1186/s12879-020-05148-7 |
work_keys_str_mv |
AT magnusunemo sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT marithansen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT ronzahadad sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT mirjapuolakkainen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT henrikwesth sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT kaisurantakokkojalava sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT carinathilesen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT michellejcole sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT irynaboiko sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT phamtlan sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT danielgolparian sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT shinito sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants AT martinsundqvist sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants |
_version_ |
1724517682614632448 |
spelling |
doaj-55b92bfe41824b28a7f9b6e4bccd75532020-11-25T03:43:54ZengBMCBMC Infectious Diseases1471-23342020-06-012011610.1186/s12879-020-05148-7Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variantsMagnus Unemo0Marit Hansen1Ronza Hadad2Mirja Puolakkainen3Henrik Westh4Kaisu Rantakokko-Jalava5Carina Thilesen6Michelle J. Cole7Iryna Boiko8Pham T. Lan9Daniel Golparian10Shin Ito11Martin Sundqvist12World Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityDepartment of Virology and Immunology, University of Helsinki and Helsinki University Hospital, HUSLABDepartment of Clinical Medicine, Faculty of Medical Sciences, University of CopenhagenDepartment of Clinical Microbiology, Turku University HospitalDepartment of Microbiology, Unilabs Laboratory MedicineNational Infection Service, Public Health EnglandWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityHanoi Medical University, National Hospital of Dermatology and VenereologyWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityiClinicWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityAbstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity of the updated AC2 for the detection of CT and Neisseria gonorrhoeae (NG) on the automated Panther system (Hologic). Methods We examined 1004 clinical AC2 samples and 225 analytical samples spiked with phenotypically and/or genetically diverse NG and CT strains, and other potentially cross-reacting microbial species. The clinical AC2 samples included CT wild type (WT)-positive (n = 488), all four described AC2 diagnostic-escape nvCTs (n = 170), NG-positive (n = 214), and CT/NG-negative (n = 202) specimens. Results All nvCT-positive samples (100%) and 486 (99.6%) of the CT WT-positive samples were positive in the updated AC2. All NG-positive, CT/NG-negative, Trichomonas vaginalis (TV)-positive, bacterial vaginosis-positive, and Candida-positive AC2 specimens gave correct results. The clinical sensitivity and specificity of the updated AC2 for CT detection was 99.7 and 100%, respectively, and for NG detection was 100% for both. Examining spiked samples, the analytical inclusivity and exclusivity were 100%, i.e., in clinically relevant concentrations of spiked microbe. Conclusions The updated AC2, including two CT targets and one NG target, showed a high sensitivity, specificity, inclusivity and exclusivity for the detection of CT WT, nvCTs, and NG. The updated AC2 on the fully automated Panther system offers a simple, rapid, high-throughput, sensitive, and specific diagnosis of CT and NG, which can easily be combined with detection of Mycoplasma genitalium and TV.http://link.springer.com/article/10.1186/s12879-020-05148-7Finnish new variantChlamydia trachomatisAptima combo 223S rRNAValidationSurveillance |